Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma.

J Clin Endocrinol Metab

Department of Endocrinology (P.d.C., L.C., M.-L.R.S.), Ambroise Paré University Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), 92100 Boulogne Billancourt, France; Medizinische Klinik IV (K.R., M.F.), Klinikum der Universität München, München 80336, Germany; Inserm U1173 (L.C., M.-L.R.-S.), Université de Versailles St-Quentin-en-Yvelines, 78280 Montigny-le-Bretonneux, France; Unité de Recherche Clinique (J.R.), Hospitalo Universitaire Paris Île-de-France Ouest, AP-HP, Hôpital Ambroise Paré, 92100 Boulogne, France; Funktionsbereich Spezielle Endokrinologie (M.S.), Universitätsklinikum Düsseldorf, 40225 Düsseldorf, Germany; Department of Endocrinology (R.L., J.B., X.B.), Cochin University Hospital, AP-HP, French Adrenal Cancer Network COrtico MEdullo-surrénale Tumeur Endocrines (COMETE)-Cancer and Unite Mixte de Recherche 8104, Institut Cochin, 75014 Paris, France; Comprehensive Cancer Center Mainfranken (A.-C.K., M.F.), University of Würzburg, Würzburg, 97080 Germany; Institut Gustave Roussy (S.L.), 94800 Villejuif, France; Department of Medicine I (T.D., M.F.), Endocrine Unit, University Hospital, University of Würzburg, Würzburg, 97080 Germany; Centre Hospitalier Régional Universitaire de Lille (C.D.C.), Lille, 59000 France; Endocrinology and Diabetes Unit (S.H), Department of Medicine I, University Hospital, University of Würzburg, 97080 Würzburg, Germany; Department of Endocrinology (D.D.), Nantes University Hospital, 44000 Nantes, France; Department of Endocrinology and Nephrology (K.M.), University of Leipzig, 04357 Leipzig, Germany; Service d'Endocrinologie Maladies Métaboliques et Nutrition (P.C.), Pôle Cardio-Vasculaire et Métabolique, Centre Hospitalier Universitaire Larrey, 10623 Toulouse, France; Division of Endocrinology and Diabetology (J.W.), University Hospital Giessen and Marburg, Campus Marburg, 35041 Marburg, Germany; Department of Endocrinology (O.C.), Michallon Teaching Hospital, 38043 Grenoble, France; Endocrinol

Published: December 2015

AI Article Synopsis

  • - Research focused on the outcomes of pregnancy in women treated for adrenocortical carcinomas (ACCs), which are aggressive tumors that may express certain hormone receptors and are often found in young women.
  • - The study compared 17 ACC patients who became pregnant after treatment to 247 nonpregnant ACC patients and analyzed survival rates and pregnancy outcomes, revealing that pregnancies were generally safe with few complications.
  • - Findings indicated that pregnancy did not significantly impact overall survival rates for these patients, although the possibility of a "healthy mother effect" (where healthier women are more likely to conceive) remains a consideration.

Article Abstract

Context: Adrenocortical carcinomas (ACCs) are rare, aggressive tumors, of which some express receptors for estradiol, progesterone, and/or human chorionic gonadotoropin. Because this disease is encountered frequently in young women, pregnancy is a relevant issue.

Objective: to evaluate the impact of pregnancy on outcome of patients previously treated for ACC.

Design/setting: retrospective observational multicenter study of the European Network for the Study of Adrenal Tumors.

Patients: Seventeen ACC patients (21 pregnancies), becoming pregnant at least 3 months after the initial treatment, were compared with 247 nonpregnant ACC patients less than 47 years old. A control group of 34 patients matched for age, sex, and tumor stage was used for survival analysis.

Main Outcome Measure(s): Overall survival, tumors characteristics at diagnosis, pregnancy outcome.

Results: All 17 patients with pregnancies had localized ACC. The median time between surgery and conception was 4 years (0.3-12 y). Two pregnancies were terminated at 8 weeks. Sixteen women gave birth to 19 live infants. With exception of 1 (presumably unrelated) cardiac malformation, no severe fetal or maternal complication was observed. After a median follow-up time of 8.36 years and 5.26 years after the first conception, 1 of the 17 patients had died and 5 had experienced a recurrence, among whom 3 occurred before conception. Overall survival was not significantly different between the "pregnancy group" and the matched controls.

Conclusion: Pregnancy in patients previously treated for ACC seems to not be associated with worse clinical outcome, although a "healthy mother effect" cannot be excluded.

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2015-2341DOI Listing

Publication Analysis

Top Keywords

patients treated
8
acc patients
8
patients pregnancies
8
patients
7
pregnancy
5
pregnancy women
4
women treated
4
treated adrenocortical
4
adrenocortical carcinoma
4
carcinoma context
4

Similar Publications

Background: Evans syndrome is a rare disorder characterized by the simultaneous or sequential combination of autoimmune hemolytic anemia and immunological thrombocytopenia, together with a positive direct antiglobulin test. This syndrome, which can be primary or secondary, is a rare initial manifestation of autoimmune diseases, notably systemic lupus erythematosus, with 1.7-2.

View Article and Find Full Text PDF

Background: Metabolic bariatric surgery is the most effective therapy for severe obesity, which affects the health of millions, most of whom are women of child-bearing age. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) are the most common bariatric procedures and are associated with durable weight loss and comorbidity resolution. Although obstetric outcomes broadly improve, the safety profile comparing the impact of RYGB and SG on obstetric outcomes is underexplored.

View Article and Find Full Text PDF

Tacrolimus-induced thrombotic microangiopathy (TMA) after heart and lung transplantation successfully treated with eculizumab.

Transpl Immunol

December 2024

Pulmonary, Critical Care and Cardiothoracic Surgery, Northwell Health Systems, 300 Community Dr, Manhasset, NY 11030, United States of America.

Introduction: Tacrolimus-induced thrombotic microangiopathy (TMA) causing acute kidney injury (AKI) without systemic features is a rare entity, particularly after non-renal solid organ transplantation.

Case Report: We describe the case of a patient with AKI after combined heart and lung transplantation. Renal biopsy revealed acute thrombotic microangiopathy which ultimately prompted initiation of eculizumab, a monoclonal antibody targeted against complement C5, with subsequent recovery in renal function.

View Article and Find Full Text PDF

A 66-year-old woman presents with unilateral orbital inflammation of several years of evolution, initially classified as idiopathic orbital inflammatory disease (IOID) subtype myositis. She presented with pain, eyelid inflammation and significant elevation of intraocular pressure, as well as radiological signs of exophthalmos and superior rectus myositis. She was treated with corticosteroids, with partial response.

View Article and Find Full Text PDF

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinoma.

Biomed Pharmacother

December 2024

Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do 15588, Republic of Korea. Electronic address:

Colorectal malignancies associated with KRAS and TP53 mutations led us to investigate the effects of combination therapy targeting KRAS, MEK1, or PLK1 in colorectal cancer. MEK1 is downstream of RAS in the MAPK pathway, whereas PLK1 is a mitotic kinase of the cell cycle activated by MAPK and regulated by p53. Bioinformatics analysis revealed that patients with colorectal cancer had a high expression of MAP2K1 and PLK1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!